公开(公告)号：WO2007052154A2

公开(公告)日：2007-05-10

申请号：PCT/IB2006/003581

申请日：2006-05-01

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  YUAN, Rui, Rong ,  LI, Wei, Ping ,  MENONNA, Joseph ,  MAEDA, Yasuhiro ,  DOWLING, Peter, C.

Inventor： YUAN, Rui, Rong ,  LI, Wei, Ping ,  MENONNA, Joseph ,  MAEDA, Yasuhiro ,  DOWLING, Peter, C.

IPC: H01R4/38

CPC classification number: C07K14/505 ,  A61K38/00 ,  A61K38/1816

Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

Abstract translation: 本发明提供了分离的稳定的EPO衍生肽及其模拟物，其在不同形式的神经和非神经器官系统损伤的受试者中防止组织损伤，含有分离的稳定的EPO衍生肽的药物组合物，治疗症状的方法 在有需要的受试者中具有炎性或自身免疫组分的疾病，病症或病状，以及有需要的受试者中下调免疫介体活性的方法。

公开(公告)号：WO2007014305A3

公开(公告)日：2007-02-01

申请号：PCT/US2006/029290

申请日：2006-07-26

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  MERCK & CO. INC. ,  PERLIN, David, S. ,  PARK, Steven ,  DOUGLAS, Cameron, M. ,  KAHN, Jennifer, Nielsen ,  PARENT, Stephen, A. ,  KELLY, Rosemarie

Inventor： PERLIN, David, S. ,  PARK, Steven ,  DOUGLAS, Cameron, M. ,  KAHN, Jennifer, Nielsen ,  PARENT, Stephen, A. ,  KELLY, Rosemarie

IPC: C12Q1/68 ,  C07H19/00 ,  C07H21/00

Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1 . Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.

公开(公告)号：WO2006124687A1

公开(公告)日：2006-11-23

申请号：PCT/US2006/018576

申请日：2006-05-12

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  WELSH, William, J. ,  PENG, Youyi ,  ZHANG, Qiang ,  KEENAN, Susan, M. ,  ARORA, Sonia

Inventor： WELSH, William, J. ,  PENG, Youyi ,  ZHANG, Qiang ,  KEENAN, Susan, M. ,  ARORA, Sonia

IPC: C07D249/08

CPC classification number: C07D249/08

Abstract: Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective amount of the opioid receptor compound to a patient in need thereof.

Abstract translation: 提出阿片受体化合物及其药物组合物。 还提出了通过向有需要的患者施用有效量的阿片受体化合物来治疗由阿片受体介导的病症的方法。

公开(公告)号：WO2006036822A1

公开(公告)日：2006-04-06

申请号：PCT/US2005/034228

申请日：2005-09-23

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  VATNER, Stephen, F. ,  DEPRE, Christopher

Inventor： VATNER, Stephen, F. ,  DEPRE, Christopher

IPC: G01N33/53 ,  C07K16/00

CPC classification number: G01N33/57496 ,  G01N33/5017 ,  G01N33/573 ,  G01N2500/10

Abstract: The present invention relates to a method for identifying an agent. for modulating cell growth or survival. The method involves the identification of an agent which modulates the net ratio of nuclear-localized versus cytosolic-localized H1l kinase or mutant H11 kinase in a cell. A method for diagnosing a cancer associated with Hll kinase or Akt activation in a subject is also provided.

Abstract translation: 本发明涉及一种鉴定药剂的方法。 用于调节细胞生长或存活。 该方法包括鉴定调节细胞中核定位与细胞溶质定位的H1I激酶或突变型H11激酶的净比率的试剂。 还提供了用于诊断与受试者中的Hll激酶或Akt激活相关的癌症的方法。

公开(公告)号：WO2005069935A2

公开(公告)日：2005-08-04

申请号：PCT/US2005/001703

申请日：2005-01-20

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  REISS, Michael ,  KLEINSTEIN, Judy

Inventor： REISS, Michael ,  KLEINSTEIN, Judy

IPC: C07K16/18

CPC classification number: C07K16/18 ,  G01N2333/495

Abstract: Methods are disclosed for determining the optimal biologic dose of a TGFβ receptor kinase inhibitor for administration to patients in need of such therapy and for monitoring the effectiveness of therapy with a TGFβ receptor kinase inhibitor in patients receiving such therapy. Kits comprising antibodies and reagents useful in such methods are also disclosed.

Abstract translation: 公开了用于确定用于施用于需要这种治疗的患者的TGFbeta受体激酶抑制剂的最佳生物剂量的方法，并且用于监测接受这种治疗的患者中用TGFbeta受体激酶抑制剂治疗的有效性。 还公开了包含在这些方法中有用的抗体和试剂的试剂盒。

公开(公告)号：WO2004091572A3

公开(公告)日：2004-10-28

申请号：PCT/US2004/011020

申请日：2004-04-09

Applicant: BIODELIVERY SCIENCES INTERNATIONAL, INC. ,  UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  GOULD-FOGERITE, Susan ,  MANNINO, Raphael, J. ,  AHL, Patrick ,  SHANG, Gaofeng ,  CHEN, Zi, Wei ,  KRAUSE-ELSMORE, Sara, L.

Inventor： GOULD-FOGERITE, Susan ,  MANNINO, Raphael, J. ,  AHL, Patrick ,  SHANG, Gaofeng ,  CHEN, Zi, Wei ,  KRAUSE-ELSMORE, Sara, L.

IPC: C12N15/11

Abstract: Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.

公开(公告)号：WO2004043384A2

公开(公告)日：2004-05-27

申请号：PCT/US2003/035636

申请日：2003-11-07

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  WELSH, William, J. ,  KEENAN, Susan, M. ,  DELISLE, Robert, K. ,  BALL, William, J.

Inventor： WELSH, William, J. ,  KEENAN, Susan, M. ,  DELISLE, Robert, K. ,  BALL, William, J.

IPC: A61K

CPC classification number: A61K31/00 ,  A61K31/015 ,  A61K31/12 ,  A61K31/34 ,  A61K31/35 ,  A61K31/353 ,  A61K31/38 ,  A61K31/381 ,  A61K31/40 ,  A61K31/538 ,  G06F19/16 ,  G06F19/706

Abstract: Disclosed is a novel pharmacophore and novel inotropic compositions created from the novel pharmacophore. Also disclosed are methods of making and using the novel pharmacophore and method of use of novel compositions to treat heart diseases by inhibiting Na, K-ATPase.

Abstract translation: 公开了一种新颖的药效团和由新型药效团产生的新颖的各向同性组合物。 还公开了制备和使用新型药效团和使用新型组合物通过抑制Na，K-ATP酶治疗心脏病的方法。

公开(公告)号：WO2004043340A2

公开(公告)日：2004-05-27

申请号：PCT/US2003/021954

申请日：2003-07-16

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  WIEDER, Robert

Inventor： WIEDER, Robert

IPC: A61K

CPC classification number: A61K31/203 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/503 ,  C07K16/2839 ,  C07K16/2842 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin α5β 1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy.

Abstract translation: 本发明提供诱导在骨髓中保持休眠的癌细胞的生长停滞和存活的试剂的鉴定，从而通过使用标准化学疗法或放射治疗来防止其消除。 碱性成纤维细胞生长因子（FGF-2）是骨髓基质丰富的乳腺分化因子，通过上调整合素α5β1诱导相对分化的乳腺癌细胞的生长停滞并限制其对纤连蛋白的存活。大多数FGF-2被捕 细胞未能建立纤维连接蛋白的最佳连接并发生细胞死亡。 确实附着于骨髓微环境的另一个主要成分的纤维连接蛋白的细胞保持活力并长达数周。 使用功能阻断抗体和肽，证明了α5β1纤连蛋白相互作用在维持生长停滞细胞存活中的特异性贡献。 因此，本发明允许可用于增强化疗或放射治疗活性的方法，试剂和药物组合物。

公开(公告)号：WO2004039335A2

公开(公告)日：2004-05-13

申请号：PCT/US2003/034871

申请日：2003-10-30

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  RUTGERS UNIVERSITY ,  POIANI, George ,  RILEY, David ,  KOHN, Joachim ,  KEMNITZER, John, E., II

Inventor： POIANI, George ,  RILEY, David ,  KOHN, Joachim ,  KEMNITZER, John, E., II

IPC: A61K

CPC classification number: A61K51/1234 ,  A61K9/1271 ,  A61K47/60 ,  A61K49/0032 ,  A61K49/0084 ,  A61K51/1231 ,  A61L15/26 ,  A61L27/18 ,  C08G63/6854 ,  C08G81/00 ,  C08L79/00

Abstract: A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably proline analogs, such as cis-4-hydroxy-L-proline (CHOP), 3,4-dehydro-DL-proline (DHP), (R)-(-)-2-thiazolidine-4-carboxylic acid (THP), and (S)-(-)-2-azetidinecarboxylic acid (ACA). Consistent, high loadings (>90%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. Efficient delivery and consistent release of the antifibrotic agent inhibits collagen accumulation and treats the diseases involved. Accordingly, there is a substantial reduction in the quantity of antifibrotic agent necessary, and thus a corresponding reduction in the potential for toxicity that would otherwise result from its prolonged administration.

Abstract translation: 公开了通过施用有效量的脂质体包封的共聚物缀合抗纤维化组合物来治疗涉及胶原代谢缺陷的肺动脉高压和其它疾病的方法。 抗纤维化剂优选为脯氨酸类似物，例如顺式-4-羟基-L-脯氨酸（CHOP），3,4-脱氢-DL-脯氨酸（DHP），（R） - （ - ） - 2-噻唑烷-4-酮 羧酸（THP）和（S） - （ - ） - 2-氮杂环丁烷羧酸（ACA）。 通过首先用L-赖氨酸形成二肽来实现抗纤维化剂的一致，高负载（> 90％），之后将二肽与聚合物组分共聚以形成共聚物缀合物。 聚合物优选为重均分子量为约500至约15,000的聚（乙二醇）。 抗纤维化剂的有效递送和一致释放抑制胶原蛋白积聚并治疗所涉及的疾病。 因此，所需的抗纤维化剂的量显着减少，因此由于其延长施用而导致的毒性潜力的相应降低。

公开(公告)号：WO2004037852A2

公开(公告)日：2004-05-06

申请号：PCT/US2003/033441

申请日：2003-10-21

Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ,  UNIVERSITY OF SOUTHERN CALIFORNIA ,  MANDOLA, Michael ,  STOEHLMACHER, Jan ,  LENZ, Heinz-Josef ,  LADNER, Robert

Inventor： MANDOLA, Michael ,  STOEHLMACHER, Jan ,  LENZ, Heinz-Josef ,  LADNER, Robert

IPC: C07K

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The present invention discloses a novel single nucleotide polymorphism (SNP) in the isolated 5' tandem repeats of the thymidylate synthase (TS) gene and methods for its use. The novel SNP, located in the 12th nucleotide of a 28 bp third tandem repeat (3R) of the TS gene, substitutes a C for a G, and is the variant form of the repeat. Subjects with the wild-type form of 3R have greater transcription of the TS gene than subjects with the variant form. The invention also reveals that a six base pair deletion in the 3' region of TS (-6 bp/1494) indicates mRNA instability and thus reduced production of TS. In diseased tissue, such as cancer, reduced production of TS is beneficial because it prevents the cancerous cells from growing and spreading. Analysis of either polymorphism or both together allows for prediction of a subject's response to chemotherapeutic and anti-cardiovascular disease treatments because both diseases are related to TS levels in a subject.

Abstract translation: 本发明公开了在胸苷酸合酶（TS）基因的分离的5'串联重复中的新型单核苷酸多态性（SNP）及其使用方法。 位于TS基因的28bp第三串联重复（3R）的第12个核苷酸的新型SNP用C代替G，并且是重复的变体形式。 具有野生型形式的3R的受试者比具有变体形式的受试者具有更高的TS基因转录。 本发明还揭示了在TS（-6bp / 1494）的3'区域中的6个碱基对缺失表示mRNA不稳定性，从而降低了TS的产生。 在患病组织如癌症中，减少TS的产生是有益的，因为它可防止癌细胞生长和扩散。 多态性或两者的分析可以预测受试者对化学治疗和抗心血管疾病治疗的反应，因为这两种疾病都与受试者的TS水平相关。